

TRUSCREEN GROUP LIMITED

Preliminary Final Report Consolidated Financial Statements - Unaudited

Currency is New Zealand Dollars

For the Year Ended 31 March 2026

Contents

Consolidated Summary of Profit or Loss and Other Comprehensive Income	2
Consolidated Statement of Financial Position	3
Consolidated Statement of Changes in Equity	4
Consolidated Statement of Cash Flows	5
Notes to the Financial Statements	6

TRUSCREEN GROUP LIMITED
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2026

	Note	2026	2025
		\$	\$
Revenue from the sale of goods	3	2,434,476	1,712,052
Other income	3	394,534	393,203
Product cost of goods sold		(1,666,675)	(1,196,832)
Employee benefit expenses and directors' fees		(705,496)	(856,761)
Other administration costs		(537,090)	(501,808)
Research and development expenses		(929,401)	(814,614)
Rent		-	(12,550)
Travel		(101,501)	(74,402)
Marketing and product approvals		(710,847)	(627,860)
Insurance		(142,608)	(140,162)
Shareholder relations and services		(236,730)	(107,064)
Share based payments		(36,829)	-
Borrowing cost		(14,575)	(16,678)
Loss before income tax		<u>(2,252,742)</u>	<u>(2,243,476)</u>
Income tax expense		-	-
Loss for the year		<u>(2,252,742)</u>	<u>(2,243,476)</u>
Other comprehensive income			
Item that may be reclassified subsequently to profit or loss			
Exchange differences on translating foreign subsidiary operations		169,531	(46,268)
		169,531	(46,268)
Total comprehensive loss for the year		<u>(2,083,211)</u>	<u>(2,289,744)</u>
Basic and diluted loss per share (cents)	4	<u>(0.032)</u>	<u>(0.41)</u>

The accompanying notes form part of these financial statements.

TRUSCREEN GROUP LIMITED
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2026

	Note	2026	2025
		\$	\$
CURRENT ASSETS			
Cash and cash equivalents		1,462,603	365,473
Other receivables		396,916	411,012
Trade receivables		1,026,962	22,798
Inventories		451,943	538,679
Other current assets – prepayments		225,064	203,544
TOTAL CURRENT ASSETS		<u>3,563,488</u>	<u>1,541,506</u>
NON-CURRENT ASSETS			
Intangible assets		-	-
Right of use assets		185,377	306,851
TOTAL NON-CURRENT ASSETS		<u>185,377</u>	<u>306,851</u>
TOTAL ASSETS		<u>3,748,865</u>	<u>1,848,357</u>
 CURRENT LIABILITIES			
Trade and other payables		813,211	387,317
Lease liability		159,112	133,211
Provision for employee benefits		109,511	104,096
TOTAL CURRENT LIABILITIES		<u>1,081,834</u>	<u>624,624</u>
NON-CURRENT LIABILITIES			
Provision for employee benefits		39,986	31,190
Lease liability		41,583	184,161
TOTAL NON-CURRENT LIABILITIES		<u>81,569</u>	<u>215,351</u>
TOTAL LIABILITIES		<u>1,163,403</u>	<u>839,975</u>
NET ASSETS		<u>2,585,462</u>	<u>1,008,382</u>
 EQUITY			
Issued capital	5	42,432,428	38,772,137
Share option reserve		41,374	89,643
Foreign currency translation reserve		(213,865)	(383,396)
Accumulated losses		(39,674,476)	(37,470,002)
TOTAL EQUITY		<u>2,585,462</u>	<u>1,008,382</u>

The accompanying notes form part of these financial statements.

TRUSCREEN GROUP LIMITED

**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2026**

Note	Share Capital \$	Accumulated Losses \$	Foreign Currency Translation Reserve \$	Option Reserve \$	Total \$
Balance at 1 April 2025	38,772,137	(37,470,002)	(383,396)	89,643	1,008,382
Loss for the year to 31 March 2026	-	(2,252,742)	-	-	(2,252,742)
Exchange differences on translating foreign subsidiary operations	-	-	169,531	-	169,531
Total comprehensive income for the year	-	(2,252,742)	169,531	-	(2,083,211)
Transactions with owners, in their capacity as owners					
Issue of shares	4,048,018	-	-	-	4,048,018
Share issue costs	(387,727)	-	-	-	(387,727)
Share based payments	-	48,269	-	(48,269)	-
Total transactions with owners	3,660,291	48,269	-	(48,269)	3,660,291
Balance at 31 March 2026	<u>42,432,428</u>	<u>(39,674,476)</u>	<u>(213,865)</u>	<u>41,374</u>	<u>2,585,462</u>

Note	Share Capital \$	Accumulated Losses \$	Foreign Currency Translation Reserve \$	Option Reserve \$	Total \$
Balance at 1 April 2024	38,705,945	(35,371,339)	(337,128)	234,456	3,231,934
Loss for the year to 31 March 2024	-	(2,243,476)	-	-	(2,243,476)
Exchange differences on translating foreign subsidiary operations	-	-	(46,268)	-	(46,268)
Total comprehensive income for the year	-	(2,243,476)	(46,268)	-	(2,289,744)
Transactions with owners, in their capacity as owners					
Issue of shares	66,192	-	-	-	66,192
Share issue costs	-	-	-	-	-
Share based payments	-	144,813	-	(144,813)	-
Total transactions with owners	66,192	144,813	-	(144,813)	66,192
Balance at 31 March 2025	<u>38,772,137</u>	<u>(37,470,002)</u>	<u>(383,396)</u>	<u>89,643</u>	<u>1,008,382</u>

The accompanying notes form part of these financial statements.

TRUSCREEN GROUP LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2026

	Note	2026	2025
		\$	\$
CASH FLOW FROM OPERATING ACTIVITIES			
Cash received from customers		1,472,115	1,716,718
Cash paid to suppliers and employees including GST		(4,429,805)	(4,416,220)
Cash received from research and development tax offset		482,719	447,140
Short-term lease payments not included in lease liability		-	(38,490)
Interest paid		(2,009)	(3,296)
Interest received		6,213	4,842
Net cash used in operating activities		<u>(2,470,767)</u>	<u>(2,289,306)</u>
CASH FLOW TO INVESTING ACTIVITIES			
Purchase of plant and equipment		-	-
Net cash used in investing activities		<u>-</u>	<u>-</u>
CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issue of shares		3,989,671	-
Share issue costs		(375,268)	-
Principal element of lease payments		(121,057)	(84,398)
Net cash from financing activities		<u>3,493,346</u>	<u>(84,398)</u>
Net increase/(decrease) in cash and cash equivalents		1,022,580	(2,373,704)
Cash and cash equivalents at the beginning of the financial year		365,473	2,728,036
Effects of exchange rate changes on cash and cash equivalents		74,550	11,141
Cash and cash equivalents at the end of the financial year		<u>1,462,603</u>	<u>365,473</u>

The accompanying notes form part of these financial statements.

NOTE 1. MATERIAL ACCOUNTING POLICY INFORMATION

General Information

These preliminary final unaudited consolidated financial statements and notes represent those of Truscreen Group Limited and its subsidiaries (the “Group”). References to “Truscreen” is used to refer to Truscreen Group Limited (the “Company”).

The parent company, Truscreen Group Limited, is the ultimate legal parent company of the Group and is a limited liability company incorporated and domiciled in New Zealand. It is registered under the Companies Act 1993. Truscreen is listed on the NZX and on the ASX as an ASX Foreign Exempt Listing. Truscreen is a FMC reporting entity under Part 7 of the Financial Markets Conduct Act 2013.

The registered office of the Company is Level 6 Equitable House, 57 Symonds St, Grafton, Auckland 1010, New Zealand. The Group is engaged in the business of the development, manufacture and sale of cancer detection devices and systems.

Basis of Preparation

These preliminary final financial statements have been prepared under the historical costs convention, modified by the revaluation of certain assets and liabilities as identified in specific accounting policies below.

The principal accounting policies adopted in the preparation of the financial report are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

The financial statements have been rounded to the nearest dollar.

Going Concern

The Group preliminary final unaudited financial statements have been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business.

As disclosed in the financial statements, the Group reports;

- a loss of \$2,252,742 (2025: \$2,243,476).
- net cash outflows from operating and investing activities of \$2,470,766 (2025: \$2,289,306)
- cash at year-end of \$1,462,603 (2025: \$365,473)

The Company undertook a capital raise in May 2026 raising approximately \$1.82 million in a share placement and with further funds expected in a Renounceable Rights issue to be completed on the 17 June 2026.

The Directors have undertaken a detailed cash flow forecast for the twelve months following the date of approval of this report, which shows that the business will be able to meet its debts as and when they fall due, for at least the next twelve months. The forecasts assume revenue growth from a number of markets, and takes into account current expectations of device and SUS orders from key distributors.

The Company also continues to review and reduce its cost base where appropriate.

The Board considers the cash flow forecasts to be achievable and sufficient to provide cash to cover any operating deficit and capital expenditure. The Board consider managing cash flow and working capital critical in successfully executing the strategies to achieve the business model of the Group. However, there is material uncertainty in relation to the Group’s ability to meet forecasts. These factors may cast significant doubt on the entity’s ability to continue as a going concern.

If the going concern assumption is not valid, the consequence is the Group may be unable to realise the value in its assets and discharge its liabilities in the normal course of business.

NOTE 2. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS

The Company makes estimates and assumptions concerning the future that affects the amounts reported in the financial statements. Estimates and judgments are continually evaluated and based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing material adjustments to the carrying amounts of assets and liabilities within the next financial year are discussed below:

- *Going Concern*

Refer to note 1.

- *Revenue from Contracts with Customers*

The application of NZ IFRS 15: Revenue from contracts with customers (NZ IFRS 15) requires the Directors to apply judgement in determining whether revenue can be recognised in advance of the receipt of cash.

The significant judgements adopted by the Group in applying NZ IFRS 15 criteria include:

- Determining if a contract with the customer exists;
- Determining if the entity can identify the payment terms for the services; and
- Determining whether it is probable that the entity will collect the consideration to which it is entitled.

- *Intangibles*

The carrying value of intangibles include acquired intellectual property and development costs capitalised in accordance with the accounting policy for research and development.

The intangibles were fully written off in a previous year.

Given the ongoing significant uncertainty associated with achieving revenue and profitability targets, the Directors have determined that the intangibles should remain fully impaired as at 31 March 2026.

- *Recognition of deferred taxation assets*

The benefit of deferred tax arising from tax losses and temporary differences has not been recognised.

- *Estimate of the Research and Development tax offset*

The Group receives a research and development tax offset based on 43.5% of research and development expenditure incurred. The amount is received following filing of the Group income tax returns. The Group estimates the amount of the offset assisted by external consultants and accounts for the amount as a receivable at year end.

- *Provision for inventory obsolescence*

The Group carries inventory of parts for the manufacture of the TruScreen Ultra® cervical cancer screening device. The Company will write off parts which it no longer considers usable. The Group has made a general provision for inventory obsolescence.

- *Provision for warranty*

The Group will undertake recalibration of the TruScreen Ultra® on an ongoing basis during the warranty period. While the Group will continue to undertake research and development of the product, the TruScreen Ultra® is a mature and well tested product and the Group has determined on the basis of materiality that no warranty provision is necessary.

- *Share based payments*

The Group measures the cost of equity-settled transactions with directors, employees and distributors by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined using a Black-Scholes model.

NOTE 3. REVENUE

	2026	2025
	\$	\$
Sales revenue - sale of goods ¹		
Wholesalers/distributors	1,902,752	1,712,052
Direct to customer	531,724	-
	<u>2,434,476</u>	<u>1,712,052</u>
Other income		
Research and development tax offset		
- Current year	303,550	383,236
- Prior year adjustment	85,799	(20,885)
	<u>389,349</u>	<u>362,351</u>
Foreign exchange gain	-	26,297
Interest received	5,185	4,555
	<u>394,534</u>	<u>393,203</u>

¹Ownership of goods transfers to the distributor/customer on leaving Truscreen's premises or that of the outsourced manufacturer when shipped directly to customers.

NOTE 4. EARNINGS PER SHARE

	2026	2025
Basic and Diluted loss per share:		
Net loss attributable to shareholders (\$)	(2,252,742)	(2,243,476)
Weighted average number of ordinary shares on issue	700,894,546	552,743,441
Basic and diluted loss per share (cents) (based on weighted average number of shares on issue)	<u>(0.32)</u>	<u>(0.41)</u>

NOTE 5. ISSUED CAPITAL

a) Ordinary Shares – Fully Paid

Group	2026	2026	2025	2025
	Number	\$	Number	\$
Balance at beginning of the year	554,907,719	38,772,137	552,591,116	38,705,945
Share issue - advisor	-	-	2,316,603	66,192
Shares issued for services rendered	1,701,576	35,702	-	-
Share purchase plan @ NZ\$0.02 per share	83,681,940	1,673,639	-	-
Share placement @ NZ\$0.022 per share	107,034,091	2,354,750	-	-
Foreign exchange adjustment on A\$ raise	-	(16,073)	-	-
Cost of capital raising	-	(387,727)	-	-
Balance at end of the year	<u>747,325,326</u>	<u>42,432,428</u>	<u>554,907,719</u>	<u>38,772,137</u>

NOTE 5. ISSUED CAPITAL (Continued)

No particular number of shares are authorised. There is no par value of shares.

All issued ordinary shares carry equal rights in respect of voting and the receipt of dividends, and upon winding up rank equally with regard to the Company's residual assets.

b) Options

The Company issued 204,741,031 unlisted options on 17 July 2025. The options were free attaching options to the share placement and share purchase plan announced on 29 May 2025.

The options have an exercise price of NZ\$0.022 (A\$0.02) and an expiry date of 17 July 2026. The expiry date of these options has now been extended to 17 July 2027.

NOTE 6. CASH FLOW INFORMATION

	2026	2025
	\$	\$
Reconciliation of cash flow from operations with loss after income tax		
Loss for the period	(2,252,742)	(2,243,476)
Adjusted for:		
Share based payment expense	36,829	-
Depreciation right of use assets	140,065	102,061
Unrealised exchange difference arising from translating loss	49,715	(8,894)
Operating cash flows before working capital changes	(2,026,133)	(2,150,309)
(Increase)/decrease in trade and other receivables	(1,004,163)	25,354
Increase in goods and services taxes recoverable	(50,454)	(2,182)
Increase in prepayments	(21,521)	(85,941)
Decrease/increase in inventory	86,737	(47,425)
Decrease in research and development tax offset	64,550	80,506
Increase/(decrease) in trade and other payables	466,006	(99,880)
Increase/(decrease) in employee liabilities	14,211	(9,429)
Net cash outflow from operating activities	<u>(2,470,767)</u>	<u>(2,289,306)</u>